Actinium Pharmaceuticals, Inc. – AMEX:ATNM
Actinium Pharmaceuticals stock price today
$1.66
+0.45
+38.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Actinium Pharmaceuticals stock price monthly change
-83.89%
month
Actinium Pharmaceuticals stock price quarterly change
-83.89%
quarter
Actinium Pharmaceuticals stock price yearly change
-77.27%
year
Actinium Pharmaceuticals key metrics
Market Cap | 38.99M |
Enterprise value | 119.28M |
P/E | -6.44 |
EV/Sales | 113.27 |
EV/EBITDA | -4.07 |
Price/Sales | 216.99 |
Price/Book | 3.20 |
PEG ratio | 0.34 |
EPS | -1.72 |
Revenue | N/A |
EBITDA | -49.10M |
Income | -46.45M |
Revenue Q/Q | N/A |
Revenue Y/Y | -60.29% |
Profit margin | -2885.09% |
Oper. margin | -2930.77% |
Gross margin | 6.46% |
EBIT margin | -2930.77% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeActinium Pharmaceuticals stock price history
Actinium Pharmaceuticals stock forecast
Actinium Pharmaceuticals financial statements
| Jun 2023 | 0 | -15.18M | |
|---|---|---|---|
| Sep 2023 | 0 | -13.27M | |
| Dec 2023 | 81K | -9.32M | -11511.11% |
| Mar 2024 | 0 | -8.67M |
| Sep 2025 | 4.53M | -13.97M | -307.83% |
|---|---|---|---|
| Oct 2025 | 11.9M | -2.78M | -23.43% |
| Dec 2025 | 6.09M | -13.00M | -213.31% |
| Dec 2025 | 16.5M | 139.43K | 0.85% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-16 | -0.3 | -0.38 |
|---|---|---|
| 2023-03-31 | -0.52086 | -0.43 |
| 2023-05-01 | -0.42 | -0.42 |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0% |
|---|---|
| 2020 | 0% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 99051000 | 45.97M | 46.41% |
|---|---|---|---|
| Sep 2023 | 88944000 | 45.36M | 51% |
| Dec 2023 | 81445000 | 45.06M | 55.33% |
| Mar 2024 | 88352000 | 44.49M | 50.36% |
| Jun 2023 | -13.64M | -47K | 10.04M |
|---|---|---|---|
| Sep 2023 | -11.12M | -30K | 2.86M |
| Dec 2023 | -7.49M | 0 | 1.19M |
| Mar 2024 | -7.37M | -11K | 14.76M |
Actinium Pharmaceuticals alternative data
| Aug 2023 | 49 |
|---|---|
| Sep 2023 | 49 |
| Oct 2023 | 49 |
| Nov 2023 | 49 |
| Dec 2023 | 49 |
| Jan 2024 | 49 |
| Feb 2024 | 49 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
Actinium Pharmaceuticals other data
6.16%
-11.67%
of ATNM is owned by hedge funds
33
-25
1.48M
-3.00M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2018 | 22730 | 0 |
| Apr 2018 | 5000 | 0 |
| Jun 2018 | 12000 | 0 |
| Jul 2018 | 10000 | 0 |
| Nov 2018 | 10000 | 0 |
| Dec 2018 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | O'LOUGHLIN STEVE officer: Chief Financial Officer | Common Stock | 10,000 | $0.44 | $4,350 | ||
Purchase | SETH SANDESH director, officer: Chief Execut.. | Common Stock | 10,000 | $0.44 | $4,370 | ||
Purchase | LUDWIG DALE L. officer: Chief Science & Tech. .. | Common Stock | 10,000 | $0.45 | $4,500 | ||
Purchase | SETH SANDESH director, officer: Chief Execut.. | Common stock | 10,000 | $0.79 | $7,900 | ||
Purchase | O'LOUGHLIN STEVE officer: Chief Financial Officer | Common Stock | 12,000 | $0.5 | $6,000 | ||
Purchase | SETH SANDESH director, officer: Chief Execut.. | Common Stock | 5,000 | $0.38 | $1,900 | ||
Purchase | SHETTY AJIT director | Common stock | 22,730 | $0.43 | $9,774 | ||
Purchase | RAY NITYA G. officer: Executiv.. | Common Stock | 10,000 | $0.75 | $7,500 | ||
Purchase | SETH SANDESH director, officer: Chief Execut.. | Common Stock | 33,333 | $0.75 | $25,000 | ||
Purchase | BERGER MARK STANLEY officer: Chief Medical Officer | Common stock | 5,000 | $1.11 | $5,550 |
| Patent |
|---|
Application METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC Filling date: 16 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 20 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 23 Mar 2022 Issue date: 7 Jul 2022 |
Application COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES Filling date: 24 Apr 2020 Issue date: 7 Jul 2022 |
Application COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES Filling date: 24 Apr 2020 Issue date: 30 Jun 2022 |
Application Filling date: 22 Nov 2021 Issue date: 12 May 2022 |
Application Filling date: 27 Nov 2019 Issue date: 28 Apr 2022 |
Application Filling date: 28 Dec 2021 Issue date: 21 Apr 2022 |
Grant Filling date: 25 May 2017 Issue date: 5 Apr 2022 |
Application Filling date: 2 Jan 2020 Issue date: 10 Mar 2022 |
| Insider | Compensation |
|---|---|
Mr. Sandesh C. Seth M.B.A., M.S., MBA (1964) Chairman & Chief Executive Officer | $893,190 |
Mr. Steven O'Loughlin BS (1986) Chief Financial Officer & Corporation Sec. | $420,000 |
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?
Actinium: Highly Derisked Late Stage Molecule With Successful Trial
Actinium Pharmaceuticals: Prep For February
Actinium: Overview Of A Promising Innovator
Actinium: 2 Catalysts Before End Of 2022 Could Boost Value
Actinium: SIERRA Is Progressing Well Towards Final Data Readout
Actinium: A Story Of Delays And Promises, About To Come To Fruition
-
What's the price of Actinium Pharmaceuticals stock today?
One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $1.66.
-
When is Actinium Pharmaceuticals's next earnings date?
Unfortunately, Actinium Pharmaceuticals's (ATNM) next earnings date is currently unknown.
-
Does Actinium Pharmaceuticals pay dividends?
No, Actinium Pharmaceuticals does not pay dividends.
-
How much money does Actinium Pharmaceuticals make?
Actinium Pharmaceuticals has a market capitalization of 38.99M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.14% to 81K US dollars. Actinium Pharmaceuticals made a loss 48.82M US dollars in net income (profit) last year or -$0.42 on an earnings per share basis.
-
What is Actinium Pharmaceuticals's stock symbol?
Actinium Pharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "ATNM".
-
What is Actinium Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Actinium Pharmaceuticals?
Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Actinium Pharmaceuticals's key executives?
Actinium Pharmaceuticals's management team includes the following people:
- Mr. Sandesh C. Seth M.B.A., M.S., MBA Chairman & Chief Executive Officer(age: 61, pay: $893,190)
- Mr. Steven O'Loughlin BS Chief Financial Officer & Corporation Sec.(age: 39, pay: $420,000)
-
How many employees does Actinium Pharmaceuticals have?
As Jul 2024, Actinium Pharmaceuticals employs 49 workers.
-
When Actinium Pharmaceuticals went public?
Actinium Pharmaceuticals, Inc. is publicly traded company for more then 12 years since IPO on 27 Dec 2012.
-
What is Actinium Pharmaceuticals's official website?
The official website for Actinium Pharmaceuticals is actiniumpharma.com.
-
Where are Actinium Pharmaceuticals's headquarters?
Actinium Pharmaceuticals is headquartered at 275 Madison Avenue, New York, NY.
-
How can i contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals's mailing address is 275 Madison Avenue, New York, NY and company can be reached via phone at +64 6 677 3870.
Actinium Pharmaceuticals company profile:
Actinium Pharmaceuticals, Inc.
actiniumpharma.comExchange:
AMEX
Full time employees:
49
Industry:
Biotechnology
Sector:
Healthcare
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
275 Madison Avenue
New York, NY 10016
New York, NY 10016
CIK: 0001388320
ISIN: US00507W2061
CUSIP: 00507W107
